MarketLens

Altimmune's Pemvidutide: A Dual-Threat Drug Beyond Liver Disease, Undervalued by the Market

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

Already a Pro member? Log in

SHARE THIS ON:

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

7 months ago

Altimmune's $225 Million Capital Raise: A Necessary Lifeline

6 months ago

Is the Market Overlooking These Undervalued Growth Opportunities in March 2026

7 months ago

Is the Market Finally Shifting Beyond Mega-Cap Tech

8 months ago

CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

Single administration of CIDEB siRNA reduced liver fat by up to 80% in MASLD patients, with reductions sustained through 36 weeks, as highlighted at AASLD.

REGN

Stock News•2 months ago

Structure Therapeutics: The Amylin Data Changes The Math

Structure Therapeutics' lead oral obesity drug aleniglipron showed 16.2% weight loss at 72 weeks, with low discontinuations and no DILI, de-risking its profile. ACCG-2671, an oral amylin agonist, now ...

GPCR

Stock News•4 months ago

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade

Altimmune was upgraded to Buy after raising $535M to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed significant MASH resolution and fibrosis improvement, but competition rem...

ALT

Breaking News

Top Headlines

View More →

Stock News•24 minutes ago

ALPHABET (GOOG) ALERT: Bragar Eagel & Squire, P.C Urgently Reminds Alphabet Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before December 1st

Stock News•30 minutes ago

Kaplan Fox & Kilsheimer LLP Alerts NVIDIA Corporation (NVDA) Investors to a Securities Class Action Deadline on January 8, 2027

Stock News•47 minutes ago

GOOGL, GOOG FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•48 minutes ago

Nvidia's Huang tries to project 'business as usual' in return to office after affair revelation

Stock News•1 hour ago

Altimmune's Pemvidutide: A Dual-Threat Drug Beyond Liver Disease, Undervalued by the Market

Exclusive Content for Pro Members

Related Articles

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

Altimmune's $225 Million Capital Raise: A Necessary Lifeline

Is the Market Overlooking These Undervalued Growth Opportunities in March 2026

Is the Market Finally Shifting Beyond Mega-Cap Tech

Category

You may also like

CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

Structure Therapeutics: The Amylin Data Changes The Math

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

ALPHABET (GOOG) ALERT: Bragar Eagel & Squire, P.C Urgently Reminds Alphabet Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before December 1st

Kaplan Fox & Kilsheimer LLP Alerts NVIDIA Corporation (NVDA) Investors to a Securities Class Action Deadline on January 8, 2027

GOOGL, GOOG FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Nvidia's Huang tries to project 'business as usual' in return to office after affair revelation

ALPHABET INC. GOOGL/GOOG Investors with Significant Losses Encouraged to Contact Kirby McInerney LLP About Securities Class Action